Age and aging in blood disorders: multiple myeloma.
作者信息
Zweegman Sonja, Palumbo Antonio, Bringhen Sara, Sonneveld Pieter
机构信息
Department of Hematology, VU University Medical Center, Amsterdam, the Netherlands.
Department of Hematology, University of Torino, Italy.
出版信息
Haematologica. 2014 Jul;99(7):1133-7. doi: 10.3324/haematol.2014.110296.
Abstract
摘要
相似文献
1
Age and aging in blood disorders: multiple myeloma.
Haematologica. 2014 Jul;99(7):1133-7. doi: 10.3324/haematol.2014.110296.
2
Novel therapies for multiple myeloma.
Aging (Albany NY). 2017 Aug 28;9(8):1857-1858. doi: 10.18632/aging.101284.
3
[Not Available].
Praxis (Bern 1994). 2016;105(21):1255-1260. doi: 10.1024/1661-8157/a002493.
4
Clinical characteristics of patients with relapsed multiple myeloma.
Cancer Treat Rev. 2015 Dec;41(10):827-35. doi: 10.1016/j.ctrv.2015.07.005. Epub 2015 Jul 31.
5
Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myeloma.
Blood. 2018 Nov 8;132(19):2097-2100. doi: 10.1182/blood-2018-05-851170. Epub 2018 Sep 20.
6
Prominent regression of corneal crystalline deposits in multiple myeloma after treatment with proteasome inhibitor.
Ann Hematol. 2019 Mar;98(3):793-795. doi: 10.1007/s00277-019-03614-0. Epub 2019 Jan 15.
7
Management of double-refractory multiple myeloma.
Curr Hematol Malig Rep. 2013 Dec;8(4):253-60. doi: 10.1007/s11899-013-0173-2.
8
Innovations in treatment and response evaluation in multiple myeloma.
Haematologica. 2016 May;101(5):518-20. doi: 10.3324/haematol.2016.142737.
9
Second-generation immunomodulatory drugs in leptomeningeal myeloma.
Leuk Lymphoma. 2019 Feb;60(2):550-552. doi: 10.1080/10428194.2018.1492125. Epub 2018 Jul 22.
10
Novel generation of agents with proven clinical activity in multiple myeloma.
Semin Oncol. 2013 Oct;40(5):618-33. doi: 10.1053/j.seminoncol.2013.07.005.
引用本文的文献
1
Patterns of multimorbidity in older adults with multiple myeloma: An analysis of SEER-Medicare.
PLoS One. 2025 Aug 20;20(8):e0330331. doi: 10.1371/journal.pone.0330331. eCollection 2025.
2
Cost-Effectiveness of Novel Agent Regimens for Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients in India.
Appl Health Econ Health Policy. 2024 Jul;22(4):569-582. doi: 10.1007/s40258-024-00877-1. Epub 2024 Mar 7.
3
Diagnostic and Prognostic Value of PACAP in Multiple Myeloma.
Int J Mol Sci. 2023 Jun 28;24(13):10801. doi: 10.3390/ijms241310801.
4
Metabolic Alterations in Multiple Myeloma: From Oncogenesis to Proteasome Inhibitor Resistance.
Cancers (Basel). 2023 Mar 9;15(6):1682. doi: 10.3390/cancers15061682.
5
Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma.
J Manag Care Spec Pharm. 2021 Dec;27(12):1691-1702. doi: 10.18553/jmcp.2021.27.12.1691.
6
Elucidating Carfilzomib's Induced Cardiotoxicity in an In Vivo Model of Aging: Prophylactic Potential of Metformin.
Int J Mol Sci. 2021 Oct 11;22(20):10956. doi: 10.3390/ijms222010956.
7
Approaches and Challenges in the Management of Multiple Myeloma in the Very Old: Future Treatment Prospects.
Front Med (Lausanne). 2021 Feb 25;8:612696. doi: 10.3389/fmed.2021.612696. eCollection 2021.
8
KLF10 inhibits cell growth by regulating PTTG1 in multiple myeloma under the regulation of microRNA-106b-5p.
Int J Biol Sci. 2020 May 15;16(12):2063-2071. doi: 10.7150/ijbs.45999. eCollection 2020.
9
Search for multiple myeloma risk factors using Mendelian randomization.
Blood Adv. 2020 May 26;4(10):2172-2179. doi: 10.1182/bloodadvances.2020001502.
10
A Rare Case of Early Onset Multiple Myeloma in a 20-Year-Old Female With Factor X Inhibitor.
J Hematol. 2018 May;7(2):69-71. doi: 10.14740/jh380w. Epub 2018 May 10.
本文引用的文献
1
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
J Clin Oncol. 2014 Mar 1;32(7):634-40. doi: 10.1200/JCO.2013.52.0023. Epub 2014 Jan 21.
2
The relevance of a geriatric assessment for elderly patients with a haematological malignancy--a systematic review.
Leuk Res. 2014 Mar;38(3):275-83. doi: 10.1016/j.leukres.2013.12.018. Epub 2013 Dec 30.
3
Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population.
Br J Haematol. 2014 Mar;164(5):684-93. doi: 10.1111/bjh.12685. Epub 2013 Dec 9.
4
Performance of two geriatric screening tools in older patients with cancer.
J Clin Oncol. 2014 Jan 1;32(1):19-26. doi: 10.1200/JCO.2013.51.1345. Epub 2013 Nov 25.
5
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients.
Leukemia. 2014 May;28(5):1122-8. doi: 10.1038/leu.2013.313. Epub 2013 Oct 25.
6
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Lancet Oncol. 2013 Oct;14(11):1055-1066. doi: 10.1016/S1470-2045(13)70380-2. Epub 2013 Sep 3.
7
Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis.
Br J Haematol. 2013 Oct;163(1):40-6. doi: 10.1111/bjh.12465. Epub 2013 Jul 27.
8
Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience.
J Clin Oncol. 2013 Aug 1;31(22):2806-9. doi: 10.1200/JCO.2012.46.2598. Epub 2013 Jun 24.
9
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results.
Blood. 2013 Aug 22;122(8):1376-83. doi: 10.1182/blood-2013-02-483073. Epub 2013 Jun 17.
10
Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma.
Blood. 2013 Jul 11;122(2):219-26. doi: 10.1182/blood-2013-03-487884. Epub 2013 May 22.
Zotero 插件